Immunocore Holdings plc (NASDAQ:IMCR) Shares Bought by Principal Financial Group Inc.

Principal Financial Group Inc. raised its position in shares of Immunocore Holdings plc (NASDAQ:IMCR - Free Report) by 25.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 546,318 shares of the company's stock after buying an additional 109,206 shares during the quarter. Principal Financial Group Inc. owned about 1.09% of Immunocore worth $17,007,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Primecap Management Co. CA lifted its stake in shares of Immunocore by 3,841.6% during the 2nd quarter. Primecap Management Co. CA now owns 1,951,070 shares of the company's stock valued at $66,122,000 after buying an additional 1,901,570 shares in the last quarter. Armistice Capital LLC boosted its stake in shares of Immunocore by 495.1% in the second quarter. Armistice Capital LLC now owns 976,000 shares of the company's stock worth $33,077,000 after acquiring an additional 812,000 shares during the period. Millennium Management LLC grew its position in shares of Immunocore by 124.4% during the second quarter. Millennium Management LLC now owns 600,954 shares of the company's stock worth $20,366,000 after purchasing an additional 333,167 shares in the last quarter. SG Americas Securities LLC lifted its holdings in Immunocore by 1,867.3% in the 2nd quarter. SG Americas Securities LLC now owns 160,358 shares of the company's stock worth $5,435,000 after purchasing an additional 152,207 shares in the last quarter. Finally, Candriam S.C.A. boosted its stake in Immunocore by 65.8% in the 2nd quarter. Candriam S.C.A. now owns 313,423 shares of the company's stock worth $10,621,000 after purchasing an additional 124,417 shares during the period. Hedge funds and other institutional investors own 84.50% of the company's stock.

Immunocore Stock Performance

Shares of IMCR traded up $0.13 during mid-day trading on Friday, reaching $32.75. The company had a trading volume of 118,940 shares, compared to its average volume of 519,018. The stock has a 50 day moving average of $32.48 and a two-hundred day moving average of $38.84. The company has a quick ratio of 3.76, a current ratio of 3.78 and a debt-to-equity ratio of 1.03. The stock has a market capitalization of $1.64 billion, a P/E ratio of -34.00 and a beta of 0.72. Immunocore Holdings plc has a 52-week low of $29.72 and a 52-week high of $76.98.

Immunocore (NASDAQ:IMCR - Get Free Report) last posted its earnings results on Wednesday, November 6th. The company reported $0.17 EPS for the quarter, beating analysts' consensus estimates of ($0.33) by $0.50. The firm had revenue of $80.25 million for the quarter, compared to analysts' expectations of $78.94 million. Immunocore had a negative return on equity of 12.84% and a negative net margin of 15.87%. The company's quarterly revenue was up 23.7% on a year-over-year basis. During the same period last year, the firm earned ($0.59) EPS. On average, analysts expect that Immunocore Holdings plc will post -0.96 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on IMCR shares. Needham & Company LLC cut their price objective on Immunocore from $78.00 to $71.00 and set a "buy" rating for the company in a research report on Thursday, November 7th. HC Wainwright reiterated a "buy" rating and issued a $100.00 price target on shares of Immunocore in a research report on Thursday, October 24th. Guggenheim lowered Immunocore from a "buy" rating to a "neutral" rating in a research note on Monday, October 7th. Mizuho downgraded Immunocore from an "outperform" rating to a "neutral" rating and cut their target price for the company from $72.00 to $38.00 in a research report on Monday. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Immunocore in a research report on Monday, September 9th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, Immunocore presently has a consensus rating of "Moderate Buy" and an average price target of $69.18.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.